Accepted for/Published in: JMIR Dermatology
Date Submitted: Jun 30, 2023
Date Accepted: Jul 11, 2024
Warning: This is an author submission that is not peer-reviewed or edited. Preprints - unless they show as "accepted" - should not be relied on to guide clinical practice or health-related behavior and should not be reported in news media as established information.
Artificial Intelligence in Psoriatic Disease
ABSTRACT
Background:
Artificial Intelligence (AI) is an emerging tool with many applications in numerous medical fields, including dermatology.
Objective:
Our objective is to provide an up-to-date literature review on the use of AI in psoriatic disease, including diagnostics and clinical management.
Methods:
Literature review
Results:
Although the majority of AI studies in dermatology focus on skin cancer, there is growing interest and applicability of AI models in inflammatory diseases, such as psoriasis. Psoriatic disease is a chronic, inflammatory, immune-mediated systemic condition with multiple comorbidities and a significant impact on patients’ quality of life. Advanced treatments, including biologics and small molecules, have transformed the management landscape of psoriatic disease. Nevertheless, there are still huge unmet needs. Globally, delay in the diagnosis of the disease and its severity is common due to poor access to healthcare systems. Moreover, despite the abundance of treatments, we are unable to predict which is the right medication for the right patient.
Conclusions:
Dermatologists can play a crucial role in the evolIn the future, AI and Machine Learning may be able to predict the clinical course of the disease and , in combination with molecular studies, may even be able to guide our choice of treatment.
Citation
Request queued. Please wait while the file is being generated. It may take some time.
Copyright
© The authors. All rights reserved. This is a privileged document currently under peer-review/community review (or an accepted/rejected manuscript). Authors have provided JMIR Publications with an exclusive license to publish this preprint on it's website for review and ahead-of-print citation purposes only. While the final peer-reviewed paper may be licensed under a cc-by license on publication, at this stage authors and publisher expressively prohibit redistribution of this draft paper other than for review purposes.